As in previous years, cancer products topped the list of new FDA-approved therapies in 2021. But the list of drug approvals is notable for other trends, including developments in rare diseases and regenerative medicine.
After its $39 billion takeover of Alexion, AstraZeneca has reportedly scuppered an investor group's proposed buyout of another rare disease drugmaker. The company was worried one of its former respiratory meds could be sold to competitors, Bloomberg reports.